Evolus (NASDAQ:EOLS – Get Free Report) and Cerus (NASDAQ:CERS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.
Institutional and Insider Ownership
90.7% of Evolus shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 5.6% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Evolus and Cerus, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| Cerus | 1 | 1 | 2 | 0 | 2.25 |
Earnings and Valuation
This table compares Evolus and Cerus”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $297.18 million | 1.39 | -$51.64 million | ($0.67) | -9.33 |
| Cerus | $206.13 million | 2.65 | -$15.63 million | ($0.05) | -54.60 |
Cerus has lower revenue, but higher earnings than Evolus. Cerus is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Evolus and Cerus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -14.39% | N/A | -19.03% |
| Cerus | -4.41% | -15.18% | -4.38% |
Volatility & Risk
Evolus has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Cerus has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Cerus
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
